MILAN, Italy — In patients with prostate cancer and cardiovascular disease, degarelix (Firmagon, Ferring Pharmaceuticals) is associated with fewer serious adverse events and less all-cause death ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results